SCHEMBL21296973

SCHEMBL21296973

CCOC(=O)c1nnn(Cc2ccc(OC)cc2)c1Oc1cccc(Br)c1

nearest known ligand 0.55

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
CYP19A1 P11511 7/20 0.55
ELANE P08246 1/20 0.46
MAPT P10636 4/20 0.45
AKR1C3 P42330 2/20 0.44
SMN1; SMN2 Q16637 1/20 0.44
POLB P06746 2/20 0.43
RXFP1 Q9HBX9 1/20 0.43
THRB P10828 1/20 0.43
ALOX15 P16050 1/20 0.42
L3MBTL1 Q9Y468 1/20 0.42
MEN1 O00255 1/20 0.42
HPGD P15428 1/20 0.42
KMT2A Q03164 1/20 0.42
HSD17B10 Q99714 1/20 0.42
UCHL1 P09936 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29692421 1.00 CYP19A1 (0.55) CYP19A1ELANEMAPTAKR1C3SMN1; SMN2
SCHEMBL28047047 0.92 CYP19A1 (0.50) CYP19A1MAPTAKR1C3SMN1; SMN2POLB
SCHEMBL22815769 0.90 CYP19A1 (0.50) CYP19A1ELANEMAPTSMN1; SMN2POLB
SCHEMBL21296900 0.89 CYP19A1 (0.57) CYP19A1MAPTAKR1C3SMN1; SMN2POLB
SCHEMBL23001814 0.89 CYP19A1 (0.47) CYP19A1MAPTAKR1C3SMN1; SMN2POLB
SCHEMBL29692354 0.89 CYP19A1 (0.47) CYP19A1MAPTAKR1C3SMN1; SMN2POLB
SCHEMBL21296984 0.88 AKR1C3 (0.49) CYP19A1MAPTAKR1C3POLBRXFP1
SCHEMBL22795533 0.88 CYP19A1 (0.57) CYP19A1MAPTAKR1C3SMN1; SMN2POLB
SCHEMBL21296982 0.87 CYP19A1 (0.45) CYP19A1MAPTAKR1C3SMN1; SMN2POLB
SCHEMBL18241057 0.87 CYP19A1 (0.45) CYP19A1ELANEMAPTAKR1C3SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250186441-A1 COMPOUNDS AND METHODS FOR TREATING OXALATE-RELATED DISEASES OXALURX, INC. 2025-06-12 US disclosed
US-12213976-B2 Compounds and methods for treating oxalate-related diseases OXALURX, INC. (US) 2025-02-04 US disclosed
CN-114980886-B Compounds and methods for treating oxalate-related diseases 奥沙鲁克斯公司 2024-08-09 CN disclosed
US-20230110495-A1 COMPOUNDS AND METHODS FOR TREATING OXALATE-RELATED DISEASES OXALURX, INC. 2023-04-13 US disclosed
US-11504367-B2 Compounds and methods for treating oxalate-related diseases OXALURX, INC. (US) 2022-11-22 US disclosed
CN-114980886-A Compounds and methods for treating oxalate-related diseases 奥沙鲁克斯公司 2022-08-30 CN disclosed
US-11389456-B2 Compounds and methods for treating oxalate-related diseases OXALURX, INC. (US) 2022-07-19 US disclosed
EP-4017490-A1 COMPOUNDS AND METHODS FOR TREATING OXALATE-RELATED DISEASES Oxalurx, Inc. (US) 2022-06-29 EP disclosed
US-20210052586-A1 COMPOUNDS AND METHODS FOR TREATING OXALATE-RELATED DISEASES OXALURX, INC. 2021-02-25 US disclosed
WO-2021035196-A1 COMPOUNDS AND METHODS FOR TREATING OXALATE-RELATED DISEASES OXALURX, INC. (US) 2021-02-25 WO disclosed
US-20200390778-A1 COMPOUNDS AND METHODS FOR TREATING OXALATE-RELATED DISEASES OXALURX, INC. 2020-12-17 US disclosed
US-20200390778-A1 COMPOUNDS AND METHODS FOR TREATING OXALATE-RELATED DISEASES OXALURX, INC. 2020-12-17 US disclosed
WO-2019165159-A1 COMPOUNDS AND METHODS FOR TREATING OXALATE-RELATED DISEASES OXALURX, INC. (US) 2019-08-29 WO disclosed
WO-2019165159-A1 COMPOUNDS AND METHODS FOR TREATING OXALATE-RELATED DISEASES OXALURX, INC. (US) 2019-08-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200390778-A1 COMPOUNDS AND METHODS FOR TREATING OXALATE-RELATED DISEASES XDH, PNPO, LOX CYP19A1 1777/4885ELANE 653/4885MAPT 1559/4885
US-20210052586-A1 COMPOUNDS AND METHODS FOR TREATING OXALATE-RELATED DISEASES XDH, PNPO, OAT CYP19A1 1765/4885ELANE 646/4885MAPT 1574/4885
US-11389456-B2 Compounds and methods for treating oxalate-related diseases XDH, PNPO, LOX CYP19A1 1777/4885ELANE 653/4885MAPT 1559/4885
US-11504367-B2 Compounds and methods for treating oxalate-related diseases XDH, PNPO, OAT CYP19A1 1765/4885ELANE 646/4885MAPT 1574/4885
US-20250186441-A1 COMPOUNDS AND METHODS FOR TREATING OXALATE-RELATED DISEASES XDH, PNPO, OAT CYP19A1 1765/4885ELANE 646/4885MAPT 1574/4885
US-20230110495-A1 COMPOUNDS AND METHODS FOR TREATING OXALATE-RELATED DISEASES XDH, PNPO, OAT CYP19A1 1765/4885ELANE 646/4885MAPT 1574/4885
US-12213976-B2 Compounds and methods for treating oxalate-related diseases XDH, PNPO, OAT CYP19A1 1765/4885ELANE 646/4885MAPT 1574/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.